To review the efficacy and safety data of amlodipine and the angiotensin-receptor blockers (ARBs), focusing on heart failure, angina, percutaneous coronary intervention (PCI), and renal protection.
DATA SOURCE:
A MEDLINE search (1966–December 2001) was completed using amlodipine, angiotensin-receptor antagonist, losartan, valsartan, candesartan, and telmisartan as key words. English-language articles were identified and included.
STUDY SELECTION AND DATA EXTRACTION:
All identified articles were evaluated. Articles representative of the subject matter of our review were included.
DATA SYNTHESIS:
Amlodipine and the ARBs lower blood pressure to a similar extent. Amlodipine is an effective antianginal agent, whereas ARBs are not. However, amlodipine is not effective in the treatment of heart failure; ARBs may be useful in this setting. ARBs are also effective in preserving renal function and may provide some protection from restenosis in patients who have had a PCI. The ARBs may also be useful in preventing both diabetic and nondiabetic nephropathy.
CONCLUSIONS:
Concomitant disease states should be considered when choosing between an ARB and amlodipine for the management of hypertension.
WhiteCMChowMSS. Assessment of the risk of calcium channel blockers in cardiovascular medicine. Formulary1997;32: 1146–65.
2.
LatnerAW. The top 200 of 2000: Drugs of the new millennium. Pharmacy Times2001;April:14–29.
3.
WilsonTWLacourciereYBarnesCC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. CMAJ1998;159: 469–76.
4.
KlonerRAWeinbergerMPoolJLChrysantSGPrasadRHarrisSMComparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol2001;87: 727–31.
5.
CoreaLCardoniOFogariRInnocentiPPorcellatiCProvvidenzaMValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther1996;60: 341–6.
6.
CohenHE, ed. Redbook. New Jersey: Medical Economics Company, 2002.
7.
PackerMO'ConnorCMGhaliJKPresslerMLCarsonPEBelkinRNEffect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med1996;335: 1107–14.
8.
KleimanNSCaliffRM. Results from late-breaking clinical trial sessions at ACCIS 2000 and ACC 2000. J Am Coll Cardiol2000;36: 310–25.
9.
PittBPoole-WilsonPASegalRMartinezFADicksteinKCammAJEffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial — The Losartan Heart Failure Survival Study ELITE II. Lancet2000;355: 1582–7.
10.
CohnJNTognoniG. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001;345: 1667–75.
11.
DeanfieldJEDetryJMRGLichtlenPRMagnaniBSellierPThaulowE. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: Double-blind circadian anti-ischemic program in Europe (CAPE Trial). J Am Coll Cardiol1994;24: 1460–7.
12.
AgodoaLYAppelLBakrisGLBeckGBourgoignieJBriggsJPEffect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA2001;285: 2719–28.
13.
BrennerBMCooperMEde ZeeuwDKeaneWFMitchWEParvingHHEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345: 861–9.
14.
LewisEJHunsickerLGClarkeWRBeriTPohlMALewisJBRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345: 851–60.
15.
SmithTWBraunwaldEKellyRA. The management of heart failure. In: BraunwaldE, ed. Heart disease: A textbook of cardiovascular medicine. 4th ed.Philadelphia: WB Saunders, 1992: 464–519.
16.
GoodfriendTLElliottMECattKJ. Angiotensin receptors and their antagonists. N Engl J Med1996;334: 1649–53.
17.
TotoR. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med2001;161: 1492–9.
18.
PittBSegalRMartinezFAMeurersGCowleyAJTomasIRandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet1997;349: 747–52.
19.
CohnJNTognoniGGlazerRDSpormannDHesterA. Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail1999;5: 155–60.
20.
WhiteCM. Catecholamines and their blockade in congestive heart failure. Am J Health Syst Pharm1998;55: 676–82.
21.
SwedbergKPfefferMGrangerCHeldPMcMurrayJOhlinGCandesartan in heart failure — Assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Charm-Programme Investigators. J Card Fail1999;5: 276–82.
22.
PfefferMABraunwaldEMoyeLABastaLBrownEJJr.CuddyTEEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med1992;327: 669–77.
23.
GlasserSPWestW. Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Am J Cardiol1988;62: 518–22.
24.
DaviesRFHabibiHKlinkeWPDessainPNadeauCPhaneufDEffect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol1995;25: 619–25.
25.
EzekowitzMDHossackJLMehtaJLThadaniUWeidlerDJKostukWAmlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial. Am Heart J1995;129: 527–35.
26.
LyonsDWebsterJBenjaminN. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol1997;51: 373–8.
27.
DzauVJBernsteinKCelermajerDCohenJDahlofBDeanfieldJThe relevance of tissue angiotensin-converting enzyme: Manifestation in mechanistic and endpoint data. Am J Cardiol2001;88(Suppl):1L–20L.
28.
AndersonTJElsteinEHaberHCharbonneauF. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol2000;35: 67–70.
29.
JergensenBSimonsenSEndresenKForfangKVatneKHansenJRestenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the Coronary AngioPlasty Amlodipine REStenosis study (CAPARES). J Am Coll Cardiol2000;35: 592–9.
30.
RensingBJHermansWRDeckersJWde FeyterPJTijssenJGSerruysPW. Lumen narrowing after percutaneous transluminal coronary balloon angioplasty follows a near gaussian distribution: A quantitative angiographic study in 1445 successfully dilated lesions. J Am Coll Cardiol1992;19: 939–45.
31.
BeattKJSerruysPWHugenholtzPG. Restenosis after coronary angioplasty: New standards for clinical studies. J Am Coll Cardiol1990;15: 491–8.
32.
PrattREDzauVJ. Pharmacological strategies to prevent restenosis: Lessons learned from blockade of the renin—angiotensin system. Circulation1996;93: 848–52.
33.
Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind, placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation1992;86: 100–10.
34.
FaxonDP. Effect of high-dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, randomized, double-blind, placebo-controlled trial of cilazapril, Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol1995;25: 362–9.
35.
SongJWhiteCM. Pharmacologic, pharmacokinetic and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy2000;20: 130–9.
36.
PetersSGottingBTrummelMRustHBrattstromA. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The Val-PREST trial. J Invas Cardiol2001;13: 93–7.
37.
Borch-JohnsenKFeldt-RasmussenBStrandgaardSSchrollMJensenJS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol1999;19: 1992–7.
38.
GersteinHCMannJFEYiQZinmanBDinneenSFHoogwerfBAlbuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA2001;286: 421–6.
HovindPRossingPTarnowLSmidtUMParvingHH. Progression of diabetic nephropathy. Kidney Int2001;59: 702–9.
41.
LewisEJHunsickerLGBainRPRohdeRD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med1993;329: 1456–62.
42.
Zanetti-ElshaterFPinitoreRBeretta-PiccoliCRiesenWHeinenG. Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens1994;7: 36–45.
43.
FogariRCorradiLPolettiLMalamaniGDLazzariPPretiAEffects of fosinopril amlodipine combination on microalbuminuria in hypertensive patients with type 2 diabetes (abstract). Am J Hypertension2001;14(suppl 1):28A.
44.
ParvingHHLehnertHBrochner-MortensenJGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001;345: 870–8.
45.
MuirheadNFeaganBFMahonJLewanczukRZRodgerNWBotteriFThe effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial. Cur Ther Res1999;60: 650–60.
46.
WheeldonNMVibertiGC. Microalbuminuria reduction with valsartan (abstract). Am J Hypertension2001;14(suppl 1):2A.
47.
HoldaasHHartmanABergKJLundKFauchaldP. Renal effects of losartan and amlodipine in hypertensive patients with nondiabetic nephropathy. Nephrol Dial Transplant1998;13: 3096–102.
